1/12
08:55 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
Low
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
1/12
07:01 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Medium
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
1/7
08:00 am
dtil
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Low
Report
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
12/29
03:42 am
dtil
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
Low
Report
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
12/23
07:00 am
dtil
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/4
06:44 am
dtil
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
Low
Report
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
11/26
02:14 pm
dtil
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
07:13 am
dtil
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
11/19
07:01 am
dtil
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Medium
Report
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
11/11
04:13 pm
dtil
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript [Seeking Alpha]
Neutral
Report
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript [Seeking Alpha]
11/10
06:12 pm
dtil
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
High
Report
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
11/10
05:39 pm
dtil
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts [Yahoo! Finance]
Low
Report
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts [Yahoo! Finance]
11/10
05:21 pm
dtil
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Low
Report
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
11/3
07:01 am
dtil
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
10/31
08:08 pm
dtil
Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy [Yahoo! Finance]
High
Report
Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy [Yahoo! Finance]
10/31
07:01 am
dtil
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
Low
Report
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025